Allogene Therapeutics Publicizes Publication in Nature Drugs of Knowledge from its Section 1 UNIVERSAL Research of ALLO-715 for the Remedy of Relapsed Refractory A number of Myeloma

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology firm pioneering the event of allogeneic CAR T (AlloCAR T) merchandise for most cancers, right now introduced that information from its Section 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T product candidate for relapsed/refractory (r/r) a number of myeloma (MM) has been printed in Nature Drugs.

UNIVERSAL is the primary and solely allogeneic CAR T examine to show that vital responses may be achieved with a single dose in sufferers with relapsed/refractory a number of myeloma. These preliminary examine outcomes printed in Nature Drugs reinforce our perception that ALLO-715 can induce deep, clinically significant responses in sufferers with an allogeneic cell remedy. AlloCAR T product candidates might be able to meaningfully scale back the boundaries confronted by sufferers with a number of myeloma when searching for to entry cell remedy,’ stated David Chang, M.D., Ph.D., President, Chief Govt Officer and Co-Founding father of Allogene.

Whereas new autologous CAR T therapies are a big advance for sufferers with a number of myeloma, challenges inherent to these remedies stay, together with manufacturing constraints and out-of-specification product, prolonged vein-to-vein time requiring bridging remedy or extended programs of remedy. These groundbreaking outcomes show the potential for an off-the-shelf cell remedy to be delivered on demand to sufferers at scale,’ stated Sham Mailankody, MBBS, Scientific Director of Mobile Remedy Service and Affiliate Attending Doctor, Memorial Sloan Kettering Most cancers Middle in New York, New York. ‘It’s my hope that this publication demonstrating vital proof-of-concept for allogeneic CAR T will set the stage for a lot of extra advances within the subject of cell remedy for myeloma.’

The Section 1 UNIVERSAL examine is a dose escalation trial in sufferers with closely pretreated r/r MM. The Nature Drugs publication contains information from the primary 48 sufferers enrolled with an information cutoff of October 2021. All sufferers handled have been refractory to their final line of remedy and no bridging remedy was used on this trial. Knowledge demonstrated the power for an allogeneic CAR T to realize response charges consistent with sure authorized autologous CAR T therapies and sturdy remissions with a manageable security profile whereas treating 92% of all enrolled sufferers and all product manufactured and launched as per product specs.

Up to date information from the UNIVERSAL examine have been offered on the Firm’s R&D Showcase in November 2022 and the American Society of Hematology Annual Assembly in December 2022.

About Allogene Therapeutics

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology firm pioneering the event of allogeneic chimeric antigen receptor T cell (AlloCAR T) merchandise for most cancers. Led by a administration group with vital expertise in cell remedy, Allogene is growing a pipeline of ‘off-the-shelf’ CAR T cell candidates with the aim of delivering available cell remedy on-demand, extra reliably, and at higher scale to extra sufferers.

Cautionary Be aware on Ahead-Trying Statements

This press launch incorporates forward-looking statements for functions of the protected harbor provisions of the Non-public Securities Litigation Reform Act of 1995. The press launch could, in some instances, use phrases reminiscent of ‘predicts,’ ‘believes,’ ‘potential,’ ‘proposed,’ ‘proceed,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘intends,’ ‘could,’ ‘might,’ ‘may,’ ‘will,’ ‘ought to’ or different phrases that convey uncertainty of future occasions or outcomes to determine these forward-looking statements. Ahead-looking statements embrace statements relating to intentions, beliefs, projections, outlook, analyses or present expectations regarding, amongst different issues: the power to progress the UNIVERSAL trial, together with advancing to Section 2; medical outcomes, which can materially change as extra affected person information turn out to be obtainable and the potential advantages of AlloCAR T merchandise. Varied components could trigger variations between Allogene’s expectations and precise outcomes as mentioned in higher element in Allogene’s filings with the SEC, together with with out limitation in its Kind 8-Okay filed on November 29, 2022 and below the ‘Danger Elements’ heading of its Kind 10-Q for the quarter ended September 30, 2022. Any forward-looking statements which are made on this press launch converse solely as of the date of this press launch. Allogene assumes no obligation to replace the forward-looking statements whether or not because of new data, future occasions or in any other case, after the date of this press launch.

Warning ought to be exercised relating to statements evaluating autologous CAR T information. There are variations within the medical trial design, affected person populations, printed information, follow-up occasions and the product candidates themselves, and the outcomes from the medical trials of autologous merchandise could haven’t any interpretative worth on our current or future outcomes.

AlloCAR T and TurboCAR are logos of Allogene Therapeutics, Inc.

Allogene’s AlloCAR T applications make the most of Cellectis applied sciences. The anti-BCMA AlloCAR T applications are licensed solely from Cellectis by Allogene and Allogene holds international growth and industrial rights to those AlloCAR T applications.

Contact:

Christine Cassiano

Tel: (714) 552-0326

Electronic mail: Christine.Cassiano@allogene.com